A

Advaxis Inc
F:FAD2

Watchlist Manager
Advaxis Inc
F:FAD2
Watchlist
Price: 0.0849 EUR -0.35%
Market Cap: 12.4m EUR

Operating Margin
Advaxis Inc

-278 969.2%
Current
-68 818.6%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-278 969.2%
=
Operating Profit
-36.3m
/
Revenue
13k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Advaxis Inc
F:FAD2
12.4m EUR
-278 969%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
400.9B USD
33%
US
Amgen Inc
NASDAQ:AMGN
176.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.4B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.9B USD
28%
AU
CSL Ltd
ASX:CSL
85.6B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD
8%
NL
argenx SE
XBRU:ARGX
44.8B EUR
22%
No Stocks Found

Advaxis Inc
Glance View

Market Cap
12.4m EUR
Industry
Biotechnology

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. The company is headquartered in Monmouth Junction, New Jersey and currently employs 15 full-time employees. The company went IPO on 2005-07-28. The Company’s products are based on a platform technology, which utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. The company is focused on single antigen and multiple antigen delivery products. The firm's pipeline of product candidates includes ADXS-503, which develops for treatment of non-small cell lung cancer; ADXS-504, which develops for the treatment of early-stage prostate cancer; and ADXS-PSA, which develops for the treatment of metastatic prostate cancer. Its ADXS-503 and ADXS-503 are in Phase I clinical trial. ADXS-PSA is in Phase II clinical trial. The company has completed and closed out clinical studies of Lm Technology immunotherapies in three program areas, HPV associated cancers, Personalized neoantigen-directed therapies and PSA directed therapy.

FAD2 Intrinsic Value
Not Available
A
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-278 969.2%
=
Operating Profit
-36.3m
/
Revenue
13k
What is the Operating Margin of Advaxis Inc?

Based on Advaxis Inc's most recent financial statements, the company has Operating Margin of -278 969.2%.

Back to Top